Market Research Logo

Cancer Immunotherapy Market Analysis Report By Product (Oncolytic Viral Therapies & Cancer Vaccines, Monoclonal Antibodies, Immunomodulators), By Cancer Type (Breast, Lung), and Segment Forecasts, 2019 - 2026

The global cancer immunotherapy market size is likely to reach USD 126.9 billion by 2026, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 9.6% during the forecast period. Increasing patient pool and higher mortality rate are augmenting the need for cancer immunotherapy globally. Furthermore, increasing number of approvals for new immunotherapeutic drugs is driving the global market.

Cancer immunotherapy has emerged as a new avenue for revenue generation for pharmaceutical companies. In addition, adverse effects, such as recurrence of cancer and organ failure, associated with conventional chemotherapies and rising demand for technologically advanced healthcare solutions are boosting the demand for immunotherapies. Moreover, introduction of newer drug classes, such as target receptors for multiple myeloma and checkpoint inhibitors, is poised to make way for advanced therapeutics in the market.

Introduction of new molecules has been proving to be beneficial for patients who are not responding to chemotherapy. Several new immunotherapeutic options, such as immunomodulators and CAR-T cell therapy, are in the pipeline and are being tested for their ability to provide better cancer treatment.

Monoclonal antibodies are the most widely used immunotherapeutic drugs globally. Development of monoclonal antibodies as effective immunotherapeutic options started after the approval of Blincyto (blinatumomab) by Amgen, a bispecific antibody that targets B-cell lymphoblastic leukemia. Increasing R&D pertaining to the use of monoclonal bodies as naked antigen binding antibodies, conjugated, and bispecific antibodies is resulting in discovery of new therapeutic options for cancer treatment.

Further key findings from the report suggest:

  • Majority of immunotherapy drugs are being used in treatment of cancer of lung, breast, and prostate
  • Monoclonal antibodies emerged as the largest segment because of increasing regulatory approvals and higher efficacy
  • Lung cancer accounted for the largest share in 2018 and will continue to dominate the market through 2025
  • North America was the leading revenue contributor in the market in 2018. Rising incidence of cancer and increasing demand for novel technologies are facilitating the dominance of the region during the forecast period
  • Europe is projected to witness rapid growth during the forecast period owing to rapid adoption of advanced cancer therapeutics for effective treatment
  • Some of the key players are Amgen, Inc.; AstraZeneca; F. Hoffmann La Roche Ltd.; Bayer AG; Bristol-Myers Squibb Company; Eli Lilly and Company; Merck and Co., Inc.; Novartis AG; and Pfizer, Inc.
Please note The report will be updated with the latest data and delivered to you within 3-4 business days.


Chapter 1 Methodology and Scope
1.1 Market segmentation & scope
1.2 Market definition
1.3 Information procurement
1.3.1 Purchased database
1.3.2 GVR’s internal database
1.3.3 Secondary sources & third party perspectives
1.3.4 Primary research
1.4 Information analysis
1.4.1 Data analysis models
1.5 Market formulation & data visualization
1.6 Data validation & publishing
Chapter 2 Executive Summary
2.1 Market outlook
2.2 Segment outlook
2.3 Competitive insights
Chapter 3 Cancer Immunotherapy Market Variables, Trends & Scope
3.1 Market lineage outlook
3.1.1 Parent market outlook
3.1.2 Related/ancillary market outlook
3.2 Penetration & growth prospect mapping
3.3 Product pipeline analysis, by stage
3.4 User perspective analysis
3.4.1 Consumer behavior analysis
3.4.2 Market influencer analysis
3.5 List of key end-users, by region / by product / by country
3.6 Regulatory framework
3.6.1 Reimbursement framework
3.6.2 Standards & compliances
3.7 Market dynamics
3.7.1 Market driver analysis
3.7.1.1 Introduction of newer drugs
3.7.1.2 Technological advancements
3.7.1.3 Increasing incidence of cancer
3.7.2 Market restraint analysis
3.7.2.1 Adverse effects of currently available therapies
3.7.2.2 High therapy cost and unfavorable reimbursement environment
3.7.3 Industry challenges
3.7.3.1 Unpredicatble efficacy of immuno-oncology agents
3.8 Cancer immunotherapy: market analysis tools
3.8.1 Industry analysis – Porter’s
3.8.1.1 Supplier power: (Low, large number of small scale suppliers)
3.8.1.2 Buyer power: (Low)
3.8.1.3 Substitution threat: (High)
3.8.1.4 Threat from new entrant: (Low)
3.8.1.5 Competitive rivalry: (High)
3.8.2 PESTEL analysis
3.8.2.1 Political landscape
3.8.2.2 Environmental landscape
3.8.2.3 Social landscape
3.8.2.4 Technology landscape
3.8.2.5 Legal landscape
3.8.3 Major deals & strategic alliances analysis (2015 - 2018 YTD)
3.8.3.1 Joint ventures
3.8.3.2 Mergers & acquisitions
3.8.3.3 Licensing & partnership
3.8.3.4 Technology collaborations
3.8.3.5 Strategic divestments
3.8.4 Market entry strategies
3.8.5 Case studies
Chapter 4 Cancer Immunotherapy Market: Segment Analysis, by Product, 2015 - 2026 (USD Billion)
4.1 Definitions & scope
4.2 Cancer immunotherapy market share analysis, 2018 & 2026
4.3 Segment dashboard
4.4 Global cancer immunotherapy market, by product type, 2015 to 2026
4.5 Market size & forecasts and trend analysis, 2015 to 2026
4.5.1 Monoclonal antibodies
4.5.2 Checkpoint inhibitors
4.5.3 Oncoloytic viral therapies and cancer vaccines
Chapter 5 Cancer Immunotherapy Market: Regional Market Analysis, by Application, 2015 - 2026 (USD Billion)
5.1 Definitions & scope
5.2 Cancer immunotherapy market share analysis, 2018 & 2026
5.3 Segment dashboard
5.4 Global cancer immunotherapy market, by application, 2015 to 2026
5.5 Cancer immunotherapy Market size & forecasts and trend analysis, 2015 to 2026
5.5.1 Lung cancer
5.5.1.1 Lung cancer market size & forecasts and trend analysis, 2015 to 2026
5.5.2 Breast cancer
5.5.2.1 Breast cancer market size & forecasts and trend analysis, 2015 to 2026
5.5.3 Colorectal cancer
5.5.3.1 Colorectal cancer market size & forecasts and trend analysis, 2015 to 2026
5.5.4 Melanoma
5.5.4.1 Melanoma market size & forecasts and trend analysis, 2015 to 2026
5.5.5 Prostate cancer
5.5.5.1 Prostate cancer market size & forecasts and trend analysis, 2015 to 2026
5.5.6 Head and neck cancer
5.5.6.1 Head and neck cancer market size & forecasts and trend analysis, 2015 to 2026
5.5.7 Ovarian cancer
5.5.7.1 Ovarian cancer market size & forecasts and trend analysis, 2015 to 2026
5.5.8 Pancreatic cancer
5.5.8.1 Pancreatic cancer market size & forecasts and trend analysis, 2015 to 2026
Chapter 6 Cancer Immunotherapy Market: Regional Movement Analysis, 2015 - 2026 (USD Billion)
6.1 Definitions & scope
6.2 Regional market share analysis, 2018 & 2026
6.3 Regional market dashboard
6.4 Regional market snapshot (market size, cagr, top verticals, key players, top trends)
6.5 Regional market share and leading players, 2018
6.5.1 North America
6.5.2 Europe
6.5.3 Asia Pacific
6.5.4 Latin America
6.5.5 Middle East & Africa
6.6 SWOT analysis, by factor (political & legal, economic, and technological)
6.6.1 North America
6.6.2 Europe
6.6.3 Asia Pacific
6.6.4 Latin America
6.6.5 Middle East & Africa
6.7 Market size, & forecasts, volume and trend analysis, 2019 to 2026:
6.8 North America
6.8.1 North America market estimates and forecast, 2015 - 2026 (USD Billion)
6.8.2 North America market estimates and forecast, 2015 - 2026
6.8.3 U.S.
6.8.3.1 U.S. market estimates and forecast, 2015 - 2026
6.8.4 Canada
6.8.4.1 Canada market estimates and forecast, 2015 - 2026 (USD Billion)
6.9 Europe
6.9.1 Europe market estimates and forecast, 2015 - 2026 (USD Billion)
6.9.2 Europe market estimates and forecast, by application, 2015 - 2026 (USD Billion)
6.9.3 Germany
6.9.3.1 Germany market estimates and forecast, 2015 - 2026 (USD Billion)
6.9.4 U.K.
6.9.4.1 U.K. market estimates and forecast, 2015 - 2026 (USD Billion)
6.9.5 France
6.9.5.1 France market estimates and forecast, 2015 - 2026 (USD Billion)
6.9.6 Italy
6.9.6.1 Italy market estimates and forecast, 2015 - 2026 (USD Billion)
6.9.7 Spain
6.9.7.1 Spain market estimates and forecast, 2015 - 2026 (USD Billion)
6.10 Asia Pacific
6.10.1 Asia Pacific market estimates and forecast, by country, 2015 - 2026 (USD Billion)
6.10.2 Asia Pacific market estimates and forecast, 2015 - 2026 (USD Billion)
6.10.3 China
6.10.3.1 China market estimates and forecast, 2015 - 2026 (USD Billion)
6.10.4 Japan
6.10.4.1 Japan market estimates and forecast, 2015 - 2026 (USD Billion)
6.10.5 India
6.10.5.1 India market estimates and forecast, 2015 - 2026 (USD Billion)
6.10.6 Australia
6.10.6.1 Australia market estimates and forecast, 2015 - 2026 (USD Billion)
6.10.7 South Korea
6.10.7.1 South Korea market estimates and forecast, 2015 - 2026 (USD Billion)
6.11 Latin America
6.11.1 Latin America market estimates and forecast, by country, 2015 - 2026 (USD Billion)
6.11.2 Latin America market estimates and forecast, 2015 - 2026 (USD Billion)
6.11.3 Brazil
6.11.3.1 Brazil market estimates and forecast, 2015 - 2026 (USD Billion)
6.11.4 Mexico
6.11.4.1 Mexico market estimates and forecast, 2015 - 2026 (USD Billion)
6.11.5 Argentina
6.11.5.1 Argentina market estimates and forecast, by product type, 2015 - 2026
6.11.6 Colombia
6.11.6.1 Colombia market estimates and forecast, by product type, 2015 - 2026
6.12 Middle East and Africa
6.12.1 Middle East and Africa market estimates and forecast, by country, 2015 - 2026
6.12.2 South Africa
6.12.2.1 South Africa market estimates and forecast, by product type, 2015 - 2026
6.12.3 Saudi Arabia
6.12.3.1 Saudi Arabia market estimates and forecast, by product type, 2015 - 2026
6.12.4 U.A.E.
6.12.4.1 U.A.E. market estimates and forecast, by product type, 2015 - 2026
Chapter 7 Cancer Immunotherapy Market Competitive Landscape
7.1 Recent developments & impact analysis, by key market participants
7.2 Company/competition categorization (key innovators, market leaders, emerging players)
7.3 Vendor landscape
7.3.1 List of key distributors and channel partners
7.3.2 Key customers
7.3.3 Key company market share analysis, 2018
7.4 Public companies
7.4.1 Company market position analysis
7.4.1.1 Financial performance
7.4.1.2 Geographic presence
7.4.1.3 Product portfolio
7.4.1.4 Key serviceable industries
7.4.1.5 Key alliances
7.4.1.6 Industry experience
7.4.2 Company market share/ranking, by region
7.4.3 Competitive dashboard analysis
7.4.3.1 Market differentiators
7.4.3.2 Synergy analysis, major deals & strategic analysis
7.5 Private companies
7.5.1 List of key emerging companies/ technology disruptors/ Innovators
7.5.2 Funding outlook
7.5.3 Regional network map
7.5.4 Company market position analysis
7.5.4.1 Geographic presence
7.5.4.2 Product portfolio
7.5.4.3 Key serviceable industries
7.5.4.4 Key alliances
7.5.4.5 Industry experience
7.5.5 Supplier ranking
7.6 Key companies profiled
7.6.1 AstraZeneca plc
7.6.1.1 Company overview
7.6.1.2 Financial performance
7.6.1.3 Product benchmarking
7.6.1.4 Strategic initiatives
7.6.2 Amgen, Inc.
7.6.2.1 Company overview
7.6.2.2 Financial performance
7.6.2.3 Product benchmarking
7.6.2.4 Strategic initiatives
7.6.3 F Hoffman-La Roche Ltd.
7.6.3.1 Company overview
7.6.3.2 Financial performance
7.6.3.3 Product benchmarking
7.6.3.4 Strategic initiatives
7.6.4 Bristol-Myers Squibb Co.
7.6.4.1 Company overview
7.6.4.2 Financial performance
7.6.4.3 Product benchmarking
7.6.4.4 Strategic initiatives
7.6.5 Novartis AG
7.6.5.1 Company overview
7.6.5.2 Financial performance
7.6.5.3 Product benchmarking
7.6.5.4 Strategic initiatives
7.6.6 Merck & Co., Inc.
7.6.6.1 Company overview
7.6.6.2 Product benchmarking
7.6.6.3 Strategic initiatives
7.6.7 Pfizer Inc.
7.6.7.1 Company overview
7.6.7.2 Financial performance
7.6.7.3 Product benchmarking
7.6.7.4 Strategic initiatives
List of Tables
Table 1 Cancer immunotherapy product pipeline, by stage
Table 2 North America. lung cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 3 North America breast cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 4 North America colorectal cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 5 North America prostate cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 6 North America head & neck cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 7 North America ovarian cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 8 North America pancreatic cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 9 U.S. lung cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 10 U.S. breast cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 11 U.S. colorectal cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 12 U.S. prostate cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 13 U.S. head & neck cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 14 U.S. ovarian cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 15 U.S. pancreatic cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 16 Canada lung cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 17 Canada breast cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 18 Canada colorectal cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 19 Canada prostate cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 20 Canada head & neck cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 21 Canada ovarian cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 22 Canada pancreatic cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 23 Europe. lung cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 24 Europe breast cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 25 Europe colorectal cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 26 Europe prostate cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 27 Europe head & neck cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 28 Europe ovarian cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 29 Europe pancreatic cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 30 Germany cancer statistics
Table 31 Germany. lung cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 32 Germany breast cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 33 Germany colorectal cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 34 Germany prostate cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 35 Germany head & neck cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 36 Germany ovarian cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 37 Germany pancreatic cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 38 U.K.. lung cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 39 U.K. breast cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 40 U.K. colorectal cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 41 U.K. prostate cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 42 U.K. head & neck cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 43 U.K. ovarian cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 44 U.K. pancreatic cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 45 France lung cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 46 France breast cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 47 France colorectal cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 48 France prostate cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 49 France head & neck cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 50 France ovarian cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 51 France pancreatic cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 52 Italy lung cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 53 Italy breast cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 54 Italy colorectal cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 55 Italy prostate cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 56 Italy head & neck cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 57 Italy ovarian cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 58 Italy pancreatic cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 59 Spain lung cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 60 Spain breast cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 61 Spain colorectal cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 62 Spain prostate cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 63 Spain head & neck cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 64 Spain ovarian cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 65 Spain pancreatic cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 66 Asia Pacific lung cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 67 Asia Pacific breast cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 68 Asia Pacific colorectal cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 69 Asia Pacific prostate cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 70 Asia Pacific head & neck cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 71 Asia Pacific ovarian cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 72 Asia Pacific pancreatic cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 73 China lung cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 74 China breast cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 75 China colorectal cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 76 China prostate cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 77 China head & neck cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 78 China ovarian cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 79 China pancreatic cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 80 Japan lung cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 81 Japan breast cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 82 Japan colorectal cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 83 Japan prostate cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 84 Japan head & neck cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 85 Japan ovarian cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 86 Japan pancreatic cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 88 India lung cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 89 India breast cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 90 India colorectal cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 91 India prostate cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 92 India head & neck cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 93 India ovarian cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 94 India pancreatic cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 95 Australia lung cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 96 Australia breast cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 97 Australia colorectal cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 98 Australia prostate cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 99 Australia head & neck cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 100 Australia ovarian cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 101 Australia pancreatic cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 102 South Korea lung cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 103 South Korea breast cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 104 South Korea colorectal cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 105 South Korea prostate cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 106 South Korea head & neck cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 107 South Korea ovarian cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 108 South Korea pancreatic cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 109 Latin America lung cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 110 Latin America breast cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 111 Latin America colorectal cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 112 Latin America prostate cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 113 Latin America head & neck cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 114 Latin America ovarian cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 115 Latin America pancreatic cancer immunotherapy market, by product, 2015 - 2026 (USD Billion
Table 116 Brazil lung cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 117 Brazil breast cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 118 Brazil colorectal cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 119 Brazil prostate cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 120 Brazil head & neck cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 121 Brazil ovarian cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 122 Brazil pancreatic cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 123 Mexico lung cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 124 Mexico breast cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 125 Mexico colorectal cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 126 Mexico prostate cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 127 Mexico head & neck cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 128 Mexico ovarian cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 129 Mexico pancreatic cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 130 Argentina lung cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 131 Argentina breast cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 132 Argentina colorectal cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 133 Argentina prostate cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 134 Argentina head & neck cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 135 Argentina ovarian cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 136 Argentina pancreatic cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 137 Colombia lung cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 138 Colombia breast cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 139 Colombia colorectal cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 140 Colombia prostate cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 141 Colombia head & neck cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 142 Colombia ovarian cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 143 Colombia pancreatic cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 144 Middle East & Africa lung cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 145 Middle East & Africa breast cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 146 Middle East & Africa colorectal cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 147 Middle East & Africa prostate cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 148 Middle East & Africa head & neck cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 149 Middle East & Africa ovarian cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 150 Middle East & Africa pancreatic cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 151 South Africa lung cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 152 South Africa breast cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 153 South Africa colorectal cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 154 South Africa prostate cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 155 South Africa head & neck cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 156 South Africa ovarian cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 157 South Africa pancreatic cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 158 Saudi Arabia lung cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 159 Saudi Arabia breast cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 160 Saudi Arabia colorectal cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 161 Saudi Arabia prostate cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 162 Saudi Arabia head & neck cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 163 Saudi Arabia ovarian cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 164 Saudi Arabia pancreatic cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 165 U.A.E. lung cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 166 U.A.E. breast cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 167 U.A.E. colorectal cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 168 U.A.E. prostate cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 169 U.A.E. head & neck cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 170 U.A.E. ovarian cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 171 U.A.E. pancreatic cancer immunotherapy market, by product, 2015 - 2026 (USD Billion)
Table 172 List of key distributors and channel partners
Table 173 List of key emerging companies /technology disruptors/innovators
List of Figures
Fig. 1 Cancer immunotherapy market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value chain based sizing & forecasting
Fig. 7 QFD modelling for market share assessment
Fig. 8 Cancer immunotherapy market snapshot (2018)
Fig. 9 Parent market outlook
Fig. 10 Ancillary market outlook
Fig. 11 Penetration & growth prospect mapping
Fig. 12 Cancer immunotherapy market driver impact
Fig. 13 Cancer immunotherapy market restraint impact
Fig. 14 Cancer immunotherapy market challenge
Fig. 15 Cancer immunotherapy market share, by product, 2018 & 2026 (%)
Fig. 16 Cancer immunotherapy market: product outlook and key takeaways
Fig. 17 Cancer immunotherapy market: product outlook and key takeaways
Fig. 18 Monoclonal antibodies market, 2015 - 2026 (USD Billion)
Fig. 19 Checkpoint inhibitors market, 2015 - 2026 (USD Billion)
Fig. 20 Oncolytic viral therapies and cancer vaccines market, 2015 - 2026 (USD Billion)
Fig. 21 Cancer immunotherapy market share, 2018 & 2026 (%)
Fig. 22 Cancer immunotherapy market application outlook and key takeaways
Fig. 23 Cancer immunotherapy application movement analysis
Fig. 24 Lung cancer market, 2015 - 2026 (USD Billion)
Fig. 25 Breast cancer market, 2015 - 2026 (USD Billion)
Fig. 26 Colorectal cancer market, 2015 - 2026 (USD Billion)
Fig. 27 Melanoma market, 2015 - 2026 (USD Billion)
Fig. 28 Prostate cancer market, 2015 - 2026 (USD Billion)
Fig. 29 Head & neck cancer market, 2015 - 2026 (USD Billion)
Fig. 30 Ovarian cancer market, 2015 - 2026 (USD Billion)
Fig. 31 Pancreatic cancer market, 2015 - 2026 (USD Billion)
Fig. 32 Cancer immunotherapy market share, by Region, 2018 & 2026 (%)
Fig. 33 Cancer immunotherapy market application movement analysis
Fig. 34 Cancer immunotherapy market regional movement analysis, 2015 - 2026
Fig. 35 North America cancer immunotherapy market SWOT analysis
Fig. 36 Europe cancer immunotherapy market SWOT analysis
Fig. 37 Asia Pacific cancer immunotherapy market SWOT analysis
Fig. 38 Latin America cancer immunotherapy market SWOT analysis
Fig. 39 Middle East & Africa cancer immunotherapy market SWOT analysis
Fig. 40 North America
Fig. 41 North America cancer immunotherapy market, 2015 - 2026 (USD Billion)
Fig. 42 U.S. cancer immunotherapy market, 2015 - 2026 (USD Billion)
Fig. 43 Canada cancer immunotherapy market, 2015 - 2026 (USD Billion)
Fig. 44 Europe
Fig. 45 Europe cancer immunotherapy market, 2015 - 2026 (USD Billion)
Fig. 46 Germany cancer immunotherapy market, 2015 - 2026 (USD Billion)
Fig. 47 U.K. cancer immunotherapy market, 2015 - 2026 (USD Billion)
Fig. 48 France cancer immunotherapy market, 2015 - 2026 (USD Billion)
Fig. 49 Italy cancer immunotherapy market, 2015 - 2026 (USD Billion)
Fig. 50 Spain cancer immunotherapy market, 2015 - 2026 (USD Billion)
Fig. 51 Asia Pacific
Fig. 52 Asia Pacific cancer immunotherapy market, 2015 - 2026 (USD Billion)
Fig. 53 China cancer immunotherapy market, 2015 - 2026 (USD Billion)
Fig. 54 Japan cancer immunotherapy market, 2015 - 2026 (USD Billion)
Fig. 55 India cancer immunotherapy market, 2015 - 2026 (USD Billion)
Fig. 56 Australia cancer immunotherapy market, 2015 - 2026 (USD Billion)
Fig. 57 South Korea cancer immunotherapy market, 2015 - 2026 (USD Billion)
Fig. 58 Latin America
Fig. 59 Latin America cancer immunotherapy market, 2015 - 2026 (USD Billion)
Fig. 60 Brazil cancer immunotherapy market, 2015 - 2026 (USD Billion)
Fig. 61 Mexico cancer immunotherapy market, 2015 - 2026 (USD Billion)
Fig. 62 Argentina cancer immunotherapy market, 2015 - 2026 (USD Billion)
Fig. 63 Colombia cancer immunotherapy market, 2015 - 2026 (USD Billion)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report